Search Results - "Spencer, H. Trent"

Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions by Fleischer, Lauren C, Spencer, H Trent, Raikar, Sunil S

“…Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated…”
Get full text

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas by Lamb, Lawrence S., Pereboeva, Larisa, Youngblood, Samantha, Gillespie, G. Yancey, Nabors, L. Burton, Markert, James M., Dasgupta, Anindya, Langford, Catherine, Spencer, H. Trent

“…Chemotherapeutic drugs such as the alkylating agent Temozolomide (TMZ), in addition to reducing tumor mass, can also sensitize tumors to immune recognition by…”
Get full text

Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction by Zakas, Philip M, Brown, Harrison C, Knight, Kristopher, Meeks, Shannon L, Spencer, H Trent, Gaucher, Eric A, Doering, Christopher B

“…The pharmaceutical properties of coagulation factor VIII are improved by reconstructing the protein's ancestral sequence. Optimization of a protein's…”
Get full text

Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines by Raikar, Sunil S., Fleischer, Lauren C., Moot, Robert, Fedanov, Andrew, Paik, Na Yoon, Knight, Kristopher A., Doering, Christopher B., Spencer, H. Trent

“…Relapsed T-cell malignancies have poor outcomes when treated with chemotherapy, but survival after allogeneic bone marrow transplantation (BMT) approaches 50%…”
Get full text

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity by Rodriguez, Martin, Trevisan, Brady, Ramamurthy, Ritu M., George, Sunil K., Diaz, Jonathan, Alexander, Jordan, Meares, Diane, Schwahn, Denise J., Quilici, David R., Figueroa, Jorge, Gautreaux, Michael, Farland, Andrew, Atala, Anthony, Doering, Christopher B., Spencer, H. Trent, Porada, Christopher D., Almeida-Porada, Graça

“…Hemophilia A is the most common X-linked bleeding disorder affecting more than half-a-million individuals worldwide. Persons with severe hemophilia A have…”
Get full text

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials by Jonus, Hunter C., Burnham, Rebecca E., Ho, Andrew, Pilgrim, Adeiye A., Shim, Jenny, Doering, Christopher B., Spencer, H. Trent, Goldsmith, Kelly C.

“…γδ T lymphocytes represent an emerging class of cellular immunotherapy with preclinical promise to treat cancer, notably neuroblastoma. The innate-like immune…”
Get full text

The Immune Response to the fVIII Gene Therapy in Preclinical Models by Patel, Seema R, Lundgren, Taran S, Spencer, H Trent, Doering, Christopher B

“…Neutralizing antibodies to factor VIII (fVIII), referred to as "inhibitors," remain the most challenging complication post-fVIII replacement therapy…”
Get full text

Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy by Lamb, Jr, Lawrence S, Bowersock, Joscelyn, Dasgupta, Anindya, Gillespie, G Yancey, Su, Yun, Johnson, Austin, Spencer, H Trent

“…Classical approaches to immunotherapy that show promise in some malignancies have generally been disappointing when applied to high-grade brain tumors such as…”
Get full text

Directing the migration of serum-free, ex vivo -expanded Vγ9Vδ2 T cells by Parwani, Kiran K, Branella, Gianna M, Burnham, Rebecca E, Burnham, Andre J, Bustamante, Austre Y Schiaffino, Foppiani, Elisabetta Manuela, Knight, Kristopher A, Petrich, Brian G, Horwitz, Edwin M, Doering, Christopher B, Spencer, H Trent

“…Vγ9Vδ2 T cells represent a promising cancer therapy platform because the implementation of allogenic, off-the-shelf product candidates is possible. However,…”
Get full text

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII by Ramamurthy, Ritu M, Rodriguez, Martin, Ainsworth, Hannah C, Shields, Jordan, Meares, Diane, Bishop, Colin, Farland, Andrew, Langefeld, Carl D, Atala, Anthony, Doering, Christopher B, Spencer, H Trent, Porada, Christopher D, Almeida-Porada, Graça

“…Placenta-derived mesenchymal cells (PLCs) endogenously produce FVIII, which makes them ideally suited for cell-based fVIII gene delivery. We have previously…”
Get full text

Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia by Branella, Gianna M, Lee, Jasmine Y, Okalova, Jennifer, Parwani, Kiran K, Alexander, Jordan S, Arthuzo, Raquel F, Fedanov, Andrew, Yu, Bing, McCarty, David, Brown, Harrison C, Chandrakasan, Shanmuganathan, Petrich, Brian G, Doering, Christopher B, Spencer, H Trent

“…The application of immunotherapies such as chimeric antigen receptor (CAR) T therapy or bi-specific T cell engager (BiTE) therapy to manage myeloid…”
Get full text

Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor by Ronayne, Estelle K, Peters, Shaun C, Gish, Joseph S, Wilson, Celena, Spencer, H Trent, Doering, Christopher B, Lollar, Pete, Spiegel, Jr, P Clint, Childers, Kenneth C

“…Factor VIII (fVIII) is a procoagulant protein that binds to activated factor IX (fIXa) on platelet surfaces to form the intrinsic tenase complex. Due to the…”
Get full text

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model by Zoine, Jaquelyn T., Knight, Kristopher A., Fleischer, Lauren C., Sutton, Kathryn S., Goldsmith, Kelly C., Doering, Christopher B., Spencer, H. Trent

“…An effective therapy regimen for relapsed/refractory high-risk neuroblastoma (NB) includes the anti-GD2 monoclonal antibody, dinutuximab, in combination with…”
Get full text

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers by Becker, Scott A., Petrich, Brian G., Yu, Bing, Knight, Kristopher A., Brown, Harrison C., Raikar, Sunil S., Doering, Christopher B., Spencer, H. Trent

“…Adoptive cell therapy (ACT) utilizing γδ T cells is becoming a promising option for the treatment of cancer, because it offers an off-the-shelf allogeneic…”
Get full text

Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A by Brown, Harrison C, Zakas, Philip M, George, Stephan N, Parker, Ernest T, Spencer, H Trent, Doering, Christopher B

“…Potency is a key optimization parameter for hemophilia A gene therapy product candidates. Optimization strategies include promoter engineering to increase…”
Get full text

Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette by Kumar, Sandeep R.P., Xie, Jun, Hu, Shilang, Ko, Jihye, Huang, Qifeng, Brown, Harrison C., Srivastava, Alok, Markusic, David M., Doering, Christopher B., Spencer, H. Trent, Srivastava, Arun, Gao, Guangping, Herzog, Roland W.

“…Hepatic gene transfer with adeno-associated viral (AAV) vectors shows much promise for the treatment of the X-linked bleeding disorder hemophilia B in multiple…”
Get full text

Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC by Porada, Christopher D, Sanada, Chad, Kuo, Chung-Jung, Colletti, Evan, Mandeville, Walter, Hasenau, John, Zanjani, Esmail D, Moot, Robert, Doering, Christopher, Spencer, H. Trent, Almeida-Porada, Graça

“…We recently re-established a line of sheep that accurately mimics the clinical symptoms and genetics of severe hemophilia A (HA). Here, we tested a novel,…”
Get full text

Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII by Russell, Athena L., Prince, Chengyu, Lundgren, Taran S., Knight, Kristopher A., Denning, Gabriela, Alexander, Jordan S., Zoine, Jaquelyn T., Spencer, H. Trent, Chandrakasan, Shanmuganathan, Doering, Christopher B.

“…Hematopoietic stem and progenitor cell (HSPC) lentiviral gene therapy is a promising strategy toward a lifelong cure for hemophilia A (HA). The primary risks…”
Get full text

Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy by Dasgupta, Anindya, Shields, Jordan E, Spencer, H Trent

“…Multimodal therapy approaches, such as combining chemotherapy agents with cellular immunotherapy, suffers from potential drug-mediated toxicity to immune…”
Get more information

Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A by Doering, Christopher B, Denning, Gabriela, Dooriss, Kerry, Gangadharan, Bagirath, Johnston, Jennifer M, Kerstann, Keith W, McCarty, David A, Spencer, H Trent

“…Human coagulation factor VIII (fVIII) is inefficiently biosynthesized in vitro and has proven difficult to express at therapeutic levels using available…”
Get full text